PMID- 24639821
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20140318
LR  - 20220330
IS  - 1682-024X (Print)
IS  - 1681-715X (Electronic)
IS  - 1681-715X (Linking)
VI  - 30
IP  - 1
DP  - 2014 Jan
TI  - Analysis of therapeutic effect and safety of target-dose metoprolol in the 
      treatment of patients with diabetes mellitus with chronic heart failure.
PG  - 7-11
LID - 10.12669/pjms.301.3908 [doi]
AB  - OBJECTIVE: To explore the therapeutic effect and safety of target-dose metoprolol 
      in treating chronic heart failure (CHF) patients complicated with diabetes 
      mellitus (DM). Method s : One hundred and fifty-four elderly patients were 
      randomly divided into an observation group and a control group (n=77), which were 
      treated with target-dose metoprolol and conventional therapy, and routinely 
      treated respectively. The New York Heart Association (NYHA) classification, left 
      ventricular end-systolic diameter (LVESD), left ventricular end-diastolic 
      diameter (LVEDD), left ventricular ejection fraction (LVEF), 6-min walking 
      distance and medication safety of the two groups were compared. RESULTS: Compared 
      with the results before treatment, the NYHA classification, LVESD, LVEDD, LVEF 
      and 6-minutes walking distance of both groups were significantly improved 
      (P<0.05), with significantly better results in the observation group than those 
      in the control group after treatment (P<0.05). In the 6 months of follow-up, the 
      incidence of cardiac events in the observation group (3.90%) was significantly 
      lower than that of the control group (14.29%) (P<0.05). The levels of average 
      fasting blood sugar and glycosylated hemoglobin in the groups showed no 
      significant differences (P>0.05). CONCLUSION: Treating CHF patients complicated 
      with DM with target-dose metoprolol can obviously boost the cardiac function and 
      exercise tolerance, leading to satisfactory clinical therapeutic effect, high 
      security and moderate tolerance.
FAU - Liu, Xuyang
AU  - Liu X
AD  - Xuyang Liu, Department of Endocrinology, 252 Hospital of PLA, Baoding 071000, P. 
      R. China.
FAU - Zhong, Chengfu
AU  - Zhong C
AD  - Chengfu Zhong, Department of Endocrinology, 252 Hospital of PLA, Baoding 071000, 
      P. R. China.
FAU - Zhao, Pengtai
AU  - Zhao P
AD  - Pengtai Zhao, Department of Endocrinology, 252 Hospital of PLA, Baoding 071000, 
      P. R. China.
FAU - Zhang, Zhihua
AU  - Zhang Z
AD  - Zhihua Zhang, Department of Endocrinology, 252 Hospital of PLA, Baoding 071000, 
      P. R. China.
FAU - Jia, Ning
AU  - Jia N
AD  - Ning Jia, Department of Endocrinology, 252 Hospital of PLA, Baoding 071000, P. R. 
      China.
FAU - Su, Sheng'ou
AU  - Su S
AD  - Sheng'ou Su, Department of Endocrinology, Second Hospital of Hebei Medical 
      University, Shijiazhuang 050000, P. R. China.
FAU - Zou, Benliang
AU  - Zou B
AD  - Benliang Zou, Department of Endocrinology, Xiyuan Hospital CACMS, Beijing 010000, 
      P. R. China.
FAU - Song, Yuming
AU  - Song Y
AD  - Yuming Song, Department of Traditional Chinese Medicine, First Center Hospital of 
      Baoding, Baoding 071000, P. R. China.
LA  - eng
PT  - Journal Article
PL  - Pakistan
TA  - Pak J Med Sci
JT  - Pakistan journal of medical sciences
JID - 100913117
PMC - PMC3955532
OTO - NOTNLM
OT  - Chronic heart failure
OT  - Diabetes mellitus
OT  - Metoprolol
OT  - Safety
OT  - Therapeutic effect
EDAT- 2014/03/19 06:00
MHDA- 2014/03/19 06:01
PMCR- 2014/01/01
CRDT- 2014/03/19 06:00
PHST- 2013/06/04 00:00 [received]
PHST- 2013/10/28 00:00 [received]
PHST- 2013/11/06 00:00 [accepted]
PHST- 2014/03/19 06:00 [entrez]
PHST- 2014/03/19 06:00 [pubmed]
PHST- 2014/03/19 06:01 [medline]
PHST- 2014/01/01 00:00 [pmc-release]
AID - 10.12669/pjms.301.3908 [doi]
PST - ppublish
SO  - Pak J Med Sci. 2014 Jan;30(1):7-11. doi: 10.12669/pjms.301.3908.